COVID-19 through Adverse Outcome Pathways: Building networks to better understand the disease - 3rd CIAO AOP Design Workshop.
COVID-19
adverse outcome pathway
interdisciplinarity
Journal
ALTEX
ISSN: 1868-8551
Titre abrégé: ALTEX
Pays: Germany
ID NLM: 100953980
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
12
2021
accepted:
17
12
2021
entrez:
15
1
2022
pubmed:
16
1
2022
medline:
15
4
2022
Statut:
ppublish
Résumé
On April 28-29, 2021, 50 scientists from different fields of expertise met for the 3rd online CIAO workshop. The CIAO project “Modelling the Pathogenesis of COVID-19 using the Adverse Outcome Pathway (AOP) framework” aims at building a holistic assembly of the available scientific knowledge on COVID-19 using the AOP framework. An individual AOP depicts the disease progression from the initial contact with the SARS-CoV-2 virus through biological key events (KE) toward an adverse outcome such as respiratory distress, anosmia or multiorgan failure. Assembling the individual AOPs into a network highlights shared KEs as central biological nodes involved in multiple outcomes observed in COVID-19 patients. During the workshop, the KEs and AOPs established so far by the CIAO members were presented and positioned on a timeline of the disease course. Modulating factors influencing the progression and severity of the disease were also addressed as well as factors beyond purely biological phenomena. CIAO relies on an interdisciplinary crowdsourcing effort, therefore, approaches to expand the CIAO network by widening the crowd and reaching stakeholders were also discussed. To conclude the workshop, it was decided that the AOPs/KEs will be further consolidated, integrating virus variants and long COVID when relevant, while an outreach campaign will be launched to broaden the CIAO scientific crowd.
Identifiants
pubmed: 35032963
doi: 10.14573/altex.2112161
pmc: PMC10069302
mid: NIHMS1867515
doi:
Types de publication
Editorial
Langues
eng
Sous-ensembles de citation
IM
Pagination
322–335Subventions
Organisme : Intramural EPA
ID : EPA999999
Pays : United States
Références
Toxicol Sci. 2018 Jun 1;163(2):346-352
pubmed: 29850905
BMJ Open. 2020 Aug 5;10(8):e039856
pubmed: 32759252
Clin Epidemiol Glob Health. 2021 Jan-Mar;9:157-161
pubmed: 32869006
Front Pharmacol. 2021 Jan 15;11:601685
pubmed: 33519463
J Transl Med. 2020 Jul 3;18(1):270
pubmed: 32620125
Toxicol Sci. 2014 Dec;142(2):312-20
pubmed: 25466378
Front Public Health. 2021 May 19;9:638605
pubmed: 34095051
ALTEX. 2021 Mar 05;38(2):351-357
pubmed: 33677612
Mod Pathol. 2020 Nov;33(11):2128-2138
pubmed: 32572155
Nano Today. 2020 Dec;35:100945
pubmed: 32834832
Toxicology. 2013 Oct 4;312:158-65
pubmed: 23978457
JAMA. 2020 Dec 8;324(22):2251-2252
pubmed: 33206133